Join
Live feed
·
INSIDERFilingvia Quantisnow
Mersana Therapeutics Inc. logo

Director Protopapas Anna converted options into 16,750 shares and sold $3,900 worth of shares (6,191 units at $0.63), increasing direct ownership by 7% to 155,428 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
MRSN· Mersana Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRSN (Mersana Therapeutics Inc.) and more on Quantisnow.